MX2022015525A - Sales o co-cristales del acido {2-[3-ciclohexil-3-(trans-4-propoxi ciclohexil)ureido]tiazol-5-ilsulfanil}acetico y usos de los mismos. - Google Patents

Sales o co-cristales del acido {2-[3-ciclohexil-3-(trans-4-propoxi ciclohexil)ureido]tiazol-5-ilsulfanil}acetico y usos de los mismos.

Info

Publication number
MX2022015525A
MX2022015525A MX2022015525A MX2022015525A MX2022015525A MX 2022015525 A MX2022015525 A MX 2022015525A MX 2022015525 A MX2022015525 A MX 2022015525A MX 2022015525 A MX2022015525 A MX 2022015525A MX 2022015525 A MX2022015525 A MX 2022015525A
Authority
MX
Mexico
Prior art keywords
cyclohexyl
ylsulfanyl
ureido
thiazol
propoxy
Prior art date
Application number
MX2022015525A
Other languages
English (en)
Inventor
Jing Teng
Nathan E Gignac
Original Assignee
Vtv Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vtv Therapeutics Llc filed Critical Vtv Therapeutics Llc
Publication of MX2022015525A publication Critical patent/MX2022015525A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan en este documento sales de sodio, piperazina y clorhidrato o co-cristales de ácido {2-[3-ciclohexil-3-(trans-4-pr opoxiciclohexil)ureido]tiazol-5-ilsulfanil}acético ("Compuesto 1").
MX2022015525A 2020-06-08 2021-06-07 Sales o co-cristales del acido {2-[3-ciclohexil-3-(trans-4-propoxi ciclohexil)ureido]tiazol-5-ilsulfanil}acetico y usos de los mismos. MX2022015525A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063035996P 2020-06-08 2020-06-08
PCT/US2021/036084 WO2021252311A1 (en) 2020-06-08 2021-06-07 Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof

Publications (1)

Publication Number Publication Date
MX2022015525A true MX2022015525A (es) 2023-03-23

Family

ID=78845832

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015525A MX2022015525A (es) 2020-06-08 2021-06-07 Sales o co-cristales del acido {2-[3-ciclohexil-3-(trans-4-propoxi ciclohexil)ureido]tiazol-5-ilsulfanil}acetico y usos de los mismos.

Country Status (9)

Country Link
US (1) US20230219909A1 (es)
EP (1) EP4161640A4 (es)
JP (1) JP2023530786A (es)
KR (1) KR20230048502A (es)
CN (1) CN116194442A (es)
AU (1) AU2021289309A1 (es)
CA (1) CA3181722A1 (es)
MX (1) MX2022015525A (es)
WO (1) WO2021252311A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3093025A1 (en) 2018-06-12 2019-12-19 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06007667A (es) * 2004-01-06 2006-09-01 Novo Nordisk As Heteroaril-ureas y su uso como activadores de glucocinasa.
CN102906077B (zh) * 2010-05-26 2015-03-04 转化技术制药有限责任公司 二甲双胍与葡萄糖激酶激活剂的联合使用以及包含二甲双胍和葡萄糖激酶激活剂的组合物
AU2013262895A1 (en) * 2012-05-17 2014-11-13 Vtv Therapeutics Llc Glucokinase activator compositions for the treatment of diabetes
AU2014226292B2 (en) * 2013-03-04 2018-10-04 Vtv Therapeutics Llc Solid compositions comprising a glucokinase activator and methods of making and using the same
MX2015011109A (es) * 2013-03-04 2015-11-16 Vtv Therapeutics Llc Composiciones estables de activador de glucoquinasa.
WO2018108128A1 (zh) * 2016-12-15 2018-06-21 华领医药技术（上海）有限公司 葡萄糖激酶激活剂的口服制剂及其制备方法

Also Published As

Publication number Publication date
US20230219909A1 (en) 2023-07-13
EP4161640A1 (en) 2023-04-12
WO2021252311A1 (en) 2021-12-16
JP2023530786A (ja) 2023-07-19
AU2021289309A1 (en) 2023-01-19
KR20230048502A (ko) 2023-04-11
EP4161640A4 (en) 2024-01-17
CN116194442A (zh) 2023-05-30
CA3181722A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
AR051965A1 (es) Sales de la n-[2-( { (3r)-1-[trans-4-hidroxi-4-(6- metoxipiridin-3-il)-ciclohexil] pirrolidin-3- il} amino)-2- oxoetil]-3-(trifluormetil) benzamida
MX2022015525A (es) Sales o co-cristales del acido {2-[3-ciclohexil-3-(trans-4-propoxi ciclohexil)ureido]tiazol-5-ilsulfanil}acetico y usos de los mismos.
ATE539750T1 (de) Trans-4-ä2-ä4-(2,3-dichlorophenyl)-piperazin-1- ylü-ethylü-n,n-dimethylcarbamoyl-cyclohexylamin zur behandlung von schizophrenie
AR031944A1 (es) Sal de fosfato del inhibidor de la oxido nitrico sintasa
TN2009000459A1 (en) Metabolites of (thio) carbamoyl-cyclohexane derivatives
NO155805C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme 2-(4-(difenylmethyl)-1-piperazinyl)-eddiksyrer og deres amider og ikke-toksiske salter.
PT998473E (pt) Modificacao da forma de cristal de um derivado de n-fenil-2-pirimidinoamina processos para a sua preparacao e sua utilizacao
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
DE60234028D1 (de) Hydantion-derivate als hemmer von matrix-metalloproteinasen
CY1110358T1 (el) Υποκατεστημενα παραγωγα προπενυλ πιπεραζινης ως νεοι αναστολεις της αποακετυλασης ιστονης
NO20084516L (no) Terfenylderivater for behandling av alzheimers sykdom
MX2022001958A (es) Sal.
BRPI0607214B8 (pt) derivados de 2-(4-cianofenilamino)pirimidina inibidores de hiv, composição farmacêutica que os compreende e seus processos de preparação
CL2023001367A1 (es) Inhibidores de btk
MX2021010906A (es) Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas.
PE20050329A1 (es) Derivados de nicotinamida como inhibidores de fosfodiesterasa pde4
PL431139A1 (pl) Kompozycja farmaceutyczna bimatoprostu i tymololu
MX2021015214A (es) Compuestos para tratar enfermedad respiratoria.
HRP20050815A2 (en) 2-(butyl-1-sulfonylamino)-n-[1(r)-(6-methoxy-pyridin-3-yl)-propyl]-benzamid, the use thereof in the form of drug an pharmaceutical preparations containing said compound
GB1417402A (en) Pharmacologically active anilinobenzothiazoles
MX2023003245A (es) Derivados de amina novedosos.
GB1449802A (en) Piperazine derivatives and compositions containing them for treating parkinsons disease
BR112022003359A2 (pt) Composição de amida peptídica e método de preparação da mesma
BR112021007035A2 (pt) Composição solúvel em água
HUP0105176A2 (hu) Benzolszulfonamidszármazékok és alkalmazásuk